Andrew Elder
Deputy Managing Partner
Joined 2005
Overview
A former neurosurgeon, Andrew focuses on medical technologies and technology-enabled services to the healthcare and life-science sectors.
He also oversees management of the UCL Technology Fund, a long-standing partnership between AlbionVC and UCL Business. He has invested in sectors ranging from digital health, diagnostics and imaging, machine learning applications and therapeutics, including cell and gene therapies.
Prior to joining AlbionVC he specialised in healthcare strategy at the Boston Consulting Group (BCG). He holds degrees in Medicine and Surgery from the University of Cambridge and is a Fellow of the Royal College of Surgeons.
Personal
Andrew has recently exited from a high-pressure investment into his own health – his pursuit of a series of endurance sports. The father-of-three says he is now most at peace when exercising a little more gently. He can often be found on a board or boat, on a bike, or half-way up a mountain. He also spends time helping others via a range of mentoring and charitable roles.
Andrew currently supports Neurofenix, Healios, Aridhia, CS Genetics and The Evewell. He had previously led investments into multiple successful healthtech companies, including Dexela (Perkin Elmer), Exco Intouch, Abcodia (AIM), and MyMeds &Me.
From Stephen Grellet, a 19thCentury Quaker missionary:
ANDREW ELDER, DEPUTY MANAGING PARTNER
“ I shall pass through this world but once. Any good therefore that I can do or any kindness that I can show to any human being, let me do it now. Let me not defer or neglect it, for I shall not pass this way again.”
Featured content
Imandra at the forefront of Neurosymbolic AI— powering Amazon’s AI systems with logic-driven accuracy | WSJ
Our backed company Imandra has been featured in the Wall Street Journal for pioneering neurosymbolic AI —helping organisations like Amazon build AI systems that reason with accuracy, minimise hallucinations, and operate at scale.